In 2025, Alnylam Pharmaceuticals conducted an environmental assessment and disclosed corporate waste management data in accordance with recognized sustainability reporting standards.The company provided a breakdown of its waste by type (hazardous vs non-hazardous) and treatment method (recovery vs disposal), enabling greater transparency into its waste handling and environmental practices.
| Metric (tonnes) | 2025 | 2024 | 2023 | 2022-2019 |
|---|---|---|---|---|
Total Waste Generated | 1,080.2a | 1,064.11a | 950a | |
Total Waste Recovered | 104.21a | 80a | 75a | |
Total Hazardous Waste Generated | 820.89a | 726.11a | 546a | |
Non-Hazardous Waste Disposed | 168.39a | 266a | 334a |
You are welcome to quote or reference individual data points from this page, provided you include the following attribution with a visible, clickable link to this page: "Source: Tracenable, the global reference for ESG data"
Bulk collection, scraping, resale, or redistribution of data across multiple company profiles is not permitted without our prior written permission. For more information, see our General Terms and Conditions.
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform.
In 2025, Alnylam Pharmaceuticals generated a total of 1,080metric tonnes of waste.a
Of this amount, 9.65% of Alnylam Pharmaceuticals's total waste generated was recovered through methods such as recycling, reuse, or composting, while 90.35% was disposed of through landfilling, incineration, or combustion.a
In 2025, Alnylam Pharmaceuticals reported a total waste generation of 1,080 metric tonnes, of which 9.65% was recovered through recycling, reuse, or composting.This low recovery rate highlights limited waste diversion and suggests that Alnylam Pharmaceuticals may be relying more heavily on landfill or incineration, underscoring opportunities for stronger resource recovery initiatives.a
Since 2023, Alnylam Pharmaceuticals's total waste generation increased by 13.71%, including a 1.51%increase in 2025, indicating a persistent upward trend that may reflect scaling operations, inefficiencies in resource use, or a lack of effective waste minimization practices.a
Over the same period, Alnylam Pharmaceuticals's waste recovery rate increased by 22.2%, including a 28.32% rise in 2025, indicating growing emphasis on circularity and improved operational practices for diverting waste from disposal.a
Overall, Alnylam Pharmaceuticals has seen a consistent rise in waste generation both over the long term and in the year 2025. However, the company has also steadily improved its waste recovery performance, suggesting that it is actively working to offset the environmental consequences of increased production through enhanced circularity efforts.
In 2025, Alnylam Pharmaceuticals generated a total of 1,080 metric tonnes of waste.a
Of this amount, 75.99% of Alnylam Pharmaceuticals's total waste generated of was classified as hazardous waste, characterized by properties such as toxicity, flammability, corrosiveness, or reactivity that may pose risks to human health, ecosystems, or the environment.24.01% was identified as non-hazardous waste, generally considered less harmful and subject to lighter regulatory controls.a
Since 2023, Alnylam Pharmaceuticals's total waste generation increased by 13.71%, including a 1.51% rise in 2025, reflecting a persistent upward trend that could be linked to operational growth, inefficient material use, or limited investment in waste prevention systems.a
Over the same period, the share of hazardous waste in Alnylam Pharmaceuticals's total output increased by 32.22%, including a further 11.37% rise in 2025, suggesting a troubling upward shift toward more environmentally harmful waste streams that could raise compliance costs and environmental risks.a
Overall, Alnylam Pharmaceuticals has seen a continuous rise in both total waste and hazardous waste over time, signaling a worsening environmental impact that may require urgent reassessment of material sourcing, production processes, or waste mitigation strategies.a
In 2025, Alnylam Pharmaceuticals reported that 821 metric tonnes of its total waste output were classified as hazardous. This represents 75.99% of its overall waste generation.a
The company treated this hazardous waste using a combination of methods.Only 1.62% of hazardous waste was recovered, meaning the vast majority was treated through disposal methods such as landfilling or incineration. This raises concerns about the environmental and health risks associated with Alnylam Pharmaceuticals’s current hazardous waste practices.a